Medical device company addressing heat-related fatalities ColdVentures announced on Friday that it has partnered with Medco Sports Medicine, a provider of sports medicine supplies, to distribute its ColdVest technology.
This collaboration aims to equip athletic trainers, educators and sports medicine professionals with an essential tool to prevent and treat heat stroke in athletes and students.
ColdVest, an FDA Class 1 medical device, rapidly reduces core body temperature using patented endothermic cooling technology. Activation requires only liquid, eliminating the need for electricity, ice, or refrigeration, making it lightweight, portable, and practical for high-risk environments.
Medco Sports Medicine, with over six decades of industry trust, will serve as the exclusive distributor of ColdVest in the sports medicine market. This agreement ensures ColdVest's availability to safeguard athletes and students during training, competitions and events. By stabilizing individuals suffering from heat-related illnesses within minutes, ColdVest offers critical support until emergency medical services arrive.
Breckenridge Pharmaceutical's Everolimus Tablets for Oral Suspension receive US FDA approval
Amgen's BLINCYTO (blinatumomab) monotherapy approved in Europe
HeartBeam submits FDA 510(k) application for groundbreaking 12-lead ECG synthesis software
FDA grants Vicore Pharma Fast Track Designation for buloxibutid in idiopathic pulmonary fibrosis
FDA accepts Saol Therapeutics' SL1009 New Drug Application for Priority Review
FDA grants Regenerative Medicine Advanced Therapy designation to Beacon Therapeutics' laru-zova
AstraZeneca and Daiichi Sankyo's Enhertu approved in US for earlier treatment of breast cancer
ImmunityBio's ANKTIVA receives EMA review for BCG-unresponsive bladder cancer treatment
ColdVentures partners with Medco Sports Medicine to combat heat stroke
eNeura Inc expands access to innovative migraine treatment
Norgine and X4 advance mavorixafor approval in Europe
Median Technologies secures funding for eyonis Lung Cancer Screening software
Genprex commences Phase 2 expansion of Acclaim-3 clinical study in ES-SCLC
Biogen submits applications for higher dose regimen of nusinersen in SMA